Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Modus Therapeutics Holding AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013465
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD).

Modus Therapeutics Holding AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Dilaforette Acquires Rights to Sevuparin from Dilafor 10
Partnerships 11
Dilaforette Enters into Agreement with Arabian Gulf University 11
Ergomed Enters into Co-Development Agreement with Dilaforette 12
Equity Offering 13
Modus Therapeutics Raises USD3.6 Million in Financing 13
Acquisition 14
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 14
Modus Therapeutics Holding AB – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Clinical Trials 18
Nov 15, 2016: Karolinska Development company Modus Therapeutics’ ongoing clinical study with sevuparin in sickle cell disease expands to include adolescent patients 18
Other Significant Developments 19
Oct 24, 2016: Dilaforette changes name to Modus Therapeutics and announces intention to conduct an Initial Public Offering 19
Oct 20, 2016: Karolinska Development company Dilaforette to change name to Modus Therapeutics and announces intention to conduct an Initial Public Offering 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Key Facts 2
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Modus Therapeutics Holding AB, Deals By Therapy Area, 2011 to YTD 2017 8
Modus Therapeutics Holding AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Dilaforette Acquires Rights to Sevuparin from Dilafor 10
Dilaforette Enters into Agreement with Arabian Gulf University 11
Ergomed Enters into Co-Development Agreement with Dilaforette 12
Modus Therapeutics Raises USD3.6 Million in Financing 13
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 14
Modus Therapeutics Holding AB, Subsidiaries 17

★海外企業調査レポート[Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Swedish Orphan Biovitrum AB (SOBI):製薬・医療:M&Aディール及び事業提携情報
    Summary Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufac …
  • Mologic Ltd-医療機器分野:企業M&A・提携分析
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company’s products include bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit. Its experti …
  • Quanta Services Inc (PWR)-石油・ガス分野:企業M&A・提携分析
    Summary Quanta Services, Inc. (Quanta) is a specialized contracting services company that offers infrastructure solutions. It designs, installs, upgrades, repairs and maintains infrastructure of electric power transmission and distribution networks, substation facilities, renewable energy facilities …
  • National Beverage Corp. (FIZZ):企業の財務・戦略的SWOT分析
    National Beverage Corp. (FIZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Oracle Financial Services Software Limited (OFSS):企業の財務・戦略的SWOT分析
    Oracle Financial Services Software Limited (OFSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Unicharm Corporation (8113):企業の財務・戦略的SWOT分析
    Unicharm Corporation (8113) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • DSK Bank EAD :企業の戦略・SWOT・財務情報
    DSK Bank EAD - Strategy, SWOT and Corporate Finance Report Summary DSK Bank EAD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Big Rivers Electric Corporation:企業の発電所・SWOT分析2018
    Big Rivers Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Canada Energy Partners Inc (CE):企業の財務・戦略的SWOT分析
    Summary Canada Energy Partners Inc (Canada Energy) is a natural gas exploration and development company. The company concentrates on mid-stream supplying of water disposal services, development of a wellbore mining technology and energy or mineral exploring. Canada Energy develops a wellbore mining …
  • Fortis Inc.:企業の戦略・SWOT・財務分析
    Fortis Inc. - Strategy, SWOT and Corporate Finance Report Summary Fortis Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Aurinia Pharmaceuticals Inc (AUP):製薬・医療:M&Aディール及び事業提携情報
    Summary Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly Isotechnika Pharma Inc, is a clinical stage biopharmaceutical company which develops and commercializes therapies for the treatment of debilitating diseases. Voclosporin, the company’s product candidate under clinical developmen …
  • Hunter Oil Corp (HOC):企業の財務・戦略的SWOT分析
    Summary Hunter Oil Corp (HOC), formerly Enhanced Oil Resources Inc is an oil and gas company that offers energy production programs. The company offers production and rehabilitation of its legacy oil fields through full cycle development. It also provides full cycle development services such as rese …
  • Martin Midstream Partners LP (MMLP):企業の財務・戦略的SWOT分析
    Martin Midstream Partners LP (MMLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Deere & Company:企業の戦略・SWOT・財務情報
    Deere & Company - Strategy, SWOT and Corporate Finance Report Summary Deere & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Titanium Metals Corporation:企業の戦略・SWOT・財務情報
    Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report Summary Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Postnl N.V.
    Postnl N.V. - Strategy, SWOT and Corporate Finance Report Summary Postnl N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Australian Mines Limited:企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Scorpio Tankers Inc (STNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Scorpio Tankers Inc. (Scorpio Tankers), a part of Scorpio Group, provides marine transportation of refined petroleum products and crude oil worldwide. The company operates through a network of owned and time chartered vessels, which distribute vegetable oils, petroleum-based feedstock and re …
  • Cochlear Ltd (COH):医療機器:M&Aディール及び事業提携情報
    Summary Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions. It develops, manufactures and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include c …
  • Laing O’Rourke Plc:企業の戦略的SWOT分析
    Laing O'Rourke Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆